<i><scp>UGT</scp>1A1</i> genotype and irinotecan therapy: general review and implementation in routine practiceMarie-Christine Étienne-Grimaldi, Chantal Le Guellec, Céline Narjoz et al.|Fundamental and Clinical Pharmacology|2015Cited by 110
Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter CohortFranck E. Nicolini, Delphine Réa, Marie‐Claude Gagnieu et al.|Blood|2013Cited by 27
Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to ImatinibHélène Labussière, Franck E. Nicolini, Sandrine Hayette et al.|Blood|2008Cited by 11